Regeneron

Regeneron Pharmaceuticals is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines, including EYLEA and EYLEA HD for ophthalmology, Dupixent in immunology (co-developed with Sanofi), Libtayo and Lynozyfic in oncology and hematology, and Praluent for cardiovascular disease. Regeneron does not publish a public developer API; its Regeneron Genetics Center collaborates on large-scale genomic research via the UK Biobank, DiscovEHR, and partner platforms rather than a self-hosted API.

Regeneron is profiled on the APIs.io network. Tagged areas include Pharmaceuticals, Biotechnology, Healthcare, and Genomics.

🌐 Visit website 📡 Source on GitHub

5.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs 6 Features 3 Use Cases

PharmaceuticalsBiotechnologyHealthcareGenomics

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 5.5/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.3 / 11

Contract Governance 1.6 / 10

Discoverability 3.5 / 9

Regulatory Posture 2.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/regeneron: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Features 6

Notable capabilities this provider offers.

Ophthalmology

EYLEA and EYLEA HD anti-VEGF therapies for retinal diseases

Immunology

Dupixent for atopic dermatitis, asthma, and other IL-4/IL-13 indications

Oncology and Hematology

Libtayo, Lynozyfic, and pipeline programs in oncology

Rare Diseases

Evkeeza, Veopoz, and other rare-disease therapies

Infectious Disease

Inmazeb antibody cocktail for Ebola

Genetics Research

Regeneron Genetics Center sequencing collaborations including UK Biobank

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Regeneron Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Use Cases 3

What developers build with this provider.

Clinical Trial Discovery

Patients and HCPs locate Regeneron-sponsored trials

Drug Information

HCPs access prescribing information for Regeneron medicines

Genomic Discovery

Researchers partner with the Regeneron Genetics Center on large-cohort sequencing

Resources

Get Started 1

Portal, sign-up, and the first successful call

ClinicalTrials

ClinicalTrials

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Vocabulary

Vocabulary

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 4

The organization behind the API

LinkedIn

Website

Website

InvestorRelations

InvestorRelations

Careers

Careers

Other 1

Properties that don't map to a standard resource type

GeneticsCenter

GeneticsCenter

Source (apis.yml)

aid: regeneron
url: https://raw.githubusercontent.com/api-evangelist/regeneron/refs/heads/main/apis.yml
name: Regeneron
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/regeneron.png
tags:
- Pharmaceuticals
- Biotechnology
- Healthcare
- Genomics
tags_raw:
- Pharmaceutical
- Biotechnology
- Healthcare
- Genomics
description: Regeneron Pharmaceuticals is a leading biotechnology company that invents, develops, and commercializes life-transforming
  medicines, including EYLEA and EYLEA HD for ophthalmology, Dupixent in immunology (co-developed with Sanofi), Libtayo and
  Lynozyfic in oncology and hematology, and Praluent for cardiovascular disease. Regeneron does not publish a public developer
  API; its Regeneron Genetics Center collaborates on large-scale genomic research via the UK Biobank, DiscovEHR, and partner
  platforms rather than a self-hosted API.
created: '2026-05-05'
modified: '2026-05-16'
specificationVersion: '0.23'
apis: []
common:
- type: DomainSecurity
  url: security/regeneron-domain-security.yml
- type: GitHubOrganization
  url: https://github.com/regeneron-mpds
- type: LinkedIn
  url: https://www.linkedin.com/company/regeneron-pharmaceuticals
- type: Website
  url: https://www.regeneron.com/
- type: InvestorRelations
  url: https://investor.regeneron.com/
- type: ClinicalTrials
  url: https://clinicaltrials.regeneron.com/
- type: Careers
  url: https://careers.regeneron.com/
- type: GeneticsCenter
  url: https://www.regeneron.com/science/regeneron-genetics-center
- type: Vocabulary
  url: vocabulary/regeneron-vocabulary.yml
- type: Features
  data:
  - name: Ophthalmology
    description: EYLEA and EYLEA HD anti-VEGF therapies for retinal diseases
  - name: Immunology
    description: Dupixent for atopic dermatitis, asthma, and other IL-4/IL-13 indications
  - name: Oncology and Hematology
    description: Libtayo, Lynozyfic, and pipeline programs in oncology
  - name: Rare Diseases
    description: Evkeeza, Veopoz, and other rare-disease therapies
  - name: Infectious Disease
    description: Inmazeb antibody cocktail for Ebola
  - name: Genetics Research
    description: Regeneron Genetics Center sequencing collaborations including UK Biobank
- type: UseCases
  data:
  - name: Clinical Trial Discovery
    description: Patients and HCPs locate Regeneron-sponsored trials
  - name: Drug Information
    description: HCPs access prescribing information for Regeneron medicines
  - name: Genomic Discovery
    description: Researchers partner with the Regeneron Genetics Center on large-cohort sequencing
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com